{
    "code": "60001098",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001098",
    "time": "2019-04-12 03:47:40",
    "許可證字號": "衛部菌疫輸字第001098號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "113\/03\/11",
    "發證日期": "108\/03\/11",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA06000109801",
    "中文品名": "安捷達注射液",
    "英文品名": "AMGEVITA Solution for Injection",
    "適應症": "類風濕性關節炎\r\nAMGEVITA適用於患有中度至重度類風濕性關節炎，並且曾經對一種或超過一種的DMARDs藥物有不適當反應的成人患者，可減輕症狀與徵兆(包括主要臨床反應和臨床緩解)、抑制結構上損害的惡化。\r\nAMGEVITA可單獨使用也可以和MTX或其他DMARDs 藥物併用。\r\n乾癬性關節炎\r\n適用於對疾病緩解型抗風濕藥物無療效之成人活動性與進行性乾癬性關節炎。\r\nAMGEVITA可單獨使用也可以和MTX或其他DMARDs 藥物併用。\r\n僵直性脊椎炎\r\n適用於減輕患有活動性僵直性脊椎炎的患者之症狀與徵兆。\r\n克隆氏症\r\n適用於對傳統治療無效之成人中度至重度克隆氏症，可減輕症狀與徵兆及誘導與維持臨床緩解。AMGEVITA亦適用於對infliximab已經失去療效或無耐受性之成人中度至重度克隆氏症，可減輕症狀與徵兆及誘導與維持臨床緩解。\r\n乾癬\r\n對其他全身性治療，包括cyclosporine、MTX 或其他光化學療法無效、有禁忌或無法耐受之中度至重度乾癬成人患者。\r\n潰瘍性結腸炎\r\nAMGEVITA適用於對於皮質類固醇和\/或6-mercaptopurine (6-MP)或azathioprine (AZA)等傳統治療無效、或對這種療法不耐受或有醫療禁忌之中度至嚴重活動性潰瘍性結腸炎成人患者。\r\n腸道貝西氏症\r\nAMGEVITA適用於治療對傳統治療無效之腸道貝西氏症 (Intestinal Behcet’s Disease)患者。\r\n化膿性汗腺炎\r\nAMGEVITA適用於對傳統全身性療法反應不佳的進行性中到重度化膿性汗腺炎(又可稱作acne inversa ) 之成人患者。\r\n葡萄膜炎\r\nAMGEVITA適用於治療對類固醇反應不佳，或不適合使用類固醇之成年患者的非感染性中段、後段和全葡萄膜炎。\r\n小兒適應症\r\n幼年型自發性多關節炎\r\nAMGEVITA與Methotrexate併用適用於2歲及以上患有活動性幼年型自發性多關節炎，並且曾經對一種或超過一種DMARDs 藥物反應不佳之患者。AMGEVITA可單獨用於對Methotrexate無法耐受或不適合持續使用之患者。\r\n小兒克隆氏症\r\nAMGEVITA適用於對皮質類固醇及免疫調節劑 (Immunomodulators) 反應不佳之6歲或大於6歲中度至重度克隆氏症患者，可減輕症狀與徵兆及誘導與維持臨床緩解。",
    "劑型": "27D注射液劑",
    "包裝": "100支以下盒裝 0.8 mL預充填注射筆 0.4 mL預充填針筒裝 0.8 mL預充填針筒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "主成分略述": [
        "ADALIMUMAB"
    ],
    "限制項目": "02輸　入 1D須執行風險管理計畫",
    "申請商名稱": "620117N253  台灣安進藥品有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F469276000  AMGEN MANUFACTURING,LIMITED",
        "製造廠廠址": "STATE ROAD 131, KM 24.6, JUNCOS, PUERTO RICO, 00777-4060, USA",
        "製造廠公司地址": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "F460325000  AMGEN INC.",
            "製造廠廠址": "ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 U.S.A.",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "原料藥製造廠"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200094700",
            "成分名稱": "ADALIMUMAB",
            "含量描述": "",
            "含量": "20.0000000000",
            "單位": "MG"
        },
        {
            "成分類別": "主成分",
            "成分代碼": "9200094700",
            "成分名稱": "ADALIMUMAB",
            "含量描述": "",
            "含量": "40.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "衛部菌疫輸字第001098號_安捷達注射液_中文仿單-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=001&Type=9"
        },
        {
            "title": "MCK01126 ART CRTN DP PFS 40 mg 501 2ct AML Line322-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=009&Type=8"
        },
        {
            "title": "MCK01125 ART CRTN DP PFS 40 mg 501 1ct AML Line322-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=008&Type=8"
        },
        {
            "title": "MCK01123 ART LBL PFS 40 mg 501 AML Line322-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=007&Type=8"
        },
        {
            "title": "MCK01121 ART LBL Device 40 mg 501 AML SC-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=006&Type=8"
        },
        {
            "title": "MCK01120 ART CRTN DP Device 40 mg 501 2ct AML-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=005&Type=8"
        },
        {
            "title": "MCK01119 ART CRTN DP Device 40 mg 501 1ct AML SC-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=004&Type=8"
        },
        {
            "title": "MCK01127 ART CRTN DP PFS 20 mg 501 2ct AML Line322-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=003&Type=8"
        },
        {
            "title": "MCK01124 ART CRTN DP PFS 20 mg 501 1ct AML Line322-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=002&Type=8"
        },
        {
            "title": "MCK01122 ART LBL PFS 20 mg 501 AML Line322-108-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001098&Seq=001&Type=8"
        }
    ]
}